<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="pr-ice-rrdlbcl-pride-zhao">
    <meta name="study:title" content="PS1956 - Interim analysis of Pomalidomide plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (PR-ICE) in relapsed/refractory diffuse large B-cell lymphoma: A Phase I/II study (PRIDE Study)">
    <meta name="study:fileName" content="Abstracts/PR-ICE-RRDLBCL-PRIDE-ZHAO-PS1956.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="2L">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="Pomalidomide,Immunomodulatory drugs,Rituximab,Monoclonal Antibody,Ifosfamide,Carboplatin,Etoposide,Chemotherapy,CIT,R-ICE">

    <title>PS1956: PR-ICE in R/R DLBCL (PRIDE Study Interim) (Zhao) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css"> </head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PS1956 - Pomalidomide + R-ICE (PR-ICE) in R/R DLBCL (PRIDE Study Interim Analysis)</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996 2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848-.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=36 enrolled)</h4>
                    <p>1st R/R DLBCL Pts (1 prior LOT). Aim: Evaluate PR-ICE (Pom + R-ICE) safety & efficacy (Phase I/II).</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention (PR-ICE Regimen)</h4>
                    <p>Phase I: Pom dose escalation (2,3,4mg D1-10) + R-ICE Q21D. MTD 2mg. Phase II: Pom 2mg + R-ICE.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M3.75 3A.75.75 0 003 3.75v16.5a.75.75 0 00.75.75h16.5a.75.75 0 00.75-.75V3.75a.75.75 0 00-.75-.75H3.75zm14.25 1.5H6v13.5h12V4.5zm-10.5 3a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5H9a.75.75 0 000-1.5H6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (N=31 evaluable)</h4>
                    <p>ORR: <span class="highlight-value">70.9%</span>, CR Rate: <span class="highlight-value">54.8%</span>. For 16 pts (3 cycles): CR Rate 87.5%.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>MTD Pom 2mg. G≥3 AEs 61.1% (Thrombocytopenia, Neutropenia, Leukopenia common). PR-ICE shows high efficacy, acceptable safety.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PS1956 - Interim analysis of Pomalidomide plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (PR-ICE) in relapsed/refractory diffuse large B-cell lymphoma: A Phase I/II study (PRIDE Study)</h1>
            <p class="abstract-sub-header">Pengpeng Xu, Yang He, Yiwen Cao, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PS1956 | Poster Presentation</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has limited treatment options and poor prognosis.</li>
                        <li>Combining lenalidomide with R-ICE has shown promising results.</li>
                        <li>Pomalidomide (Pom), a third-generation immunomodulatory agent, has shown activity in R/R primary central nervous system lymphoma (PCNSL).</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">This Phase I/II study (PRIDE Study, ChiCTR2100049327) evaluates Pomalidomide + R-ICE (PR-ICE) as salvage for first-relapse or primary refractory DLBCL. This is an interim analysis.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Patient Population: DLBCL pts with only one prior line of therapy, experiencing progression or no remission within 90 days post last dose.</li>
                        <li><strong>Phase I (Dose Escalation, 3+3 design, N=9 planned):</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>R-ICE Q21D + Pomalidomide (2mg, 3mg, or 4mg daily, D1-10).</li>
                                <li>Primary Goal: Determine MTD or recommended dose based on DLTs.</li>
                            </ul>
                        </li>
                        <li><strong>Phase II (N=44 planned):</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>Pomalidomide at MTD + R-ICE.</li>
                                <li>Primary Endpoint: CR rate.</li>
                                <li>Secondary Endpoints: ORR, 2-year PFS, 2-year OS, safety.</li>
                            </ul>
                        </li>
                        <li>Efficacy Assessment: After 2 and 3 treatment cycles.</li>
                        <li>Data Cutoff: February 14, 2025.</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">PRIDE Study (Phase I/II) Design</h3>
                        <div class="schema-enrollment">
                            <strong>1st R/R DLBCL Pts (1 prior LOT)</strong>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase cohort-a" style="flex-basis: 48%;">
                                <strong>Phase I (Dose Escalation)</strong>
                                <span>R-ICE (Q21D) + Pomalidomide</span>
                                <span>(2mg, 3mg, or 4mg PO D1-10)</span>
                                <span>(3+3 Design, N=9 planned)</span>
                                <span>Goal: Determine MTD</span>
                            </div>
                             <div class="schema-phase cohort-b" style="flex-basis: 48%;">
                                <strong>Phase II (Expansion)</strong>
                                <span>Pomalidomide (at MTD)</span>
                                <span>+ R-ICE (Q21D)</span>
                                <span>(N=44 planned)</span>
                                <span>Primary EP: CR Rate</span>
                            </div>
                        </div>
                        <div class="schema-assessment-points">
                           <span>Efficacy: CR, ORR (after 2 & 3 cycles)</span>
                           <span>Survival: 2-yr PFS, 2-yr OS</span>
                           <span>Safety: DLTs (Phase I), AEs</span>
                        </div>
                    </div>
                </div>
            </div> <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=36 Enrolled)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Median Age: 61 years.</li>
                        <li>ECOG Score 0-1: 33 patients.</li>
                        <li>Phase I Dose Escalation: 7 patients treated (3 at 2mg Pom, 4 at 3mg Pom).</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy & MTD Results (Interim)</h2>
                    <p class="text-sm font-semibold mt-1 mb-1">MTD Determination (Phase I):</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>DLTs in 3mg cohort: Grade 4 thrombocytopenia, Grade 4 rash.</li>
                        <li>MTD of Pomalidomide: <strong>2 mg</strong> daily on days 1-10 with R-ICE.</li>
                    </ul>
                    <p class="text-sm font-semibold mt-3 mb-1">Overall Efficacy (N=31 evaluable):</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li><strong>Overall Response Rate (ORR): 70.9%</strong> (22/31)</li>
                        <li><strong>Complete Response (CR) Rate: 54.8%</strong> (17/31)</li>
                        <li>Partial Response (PR): 5 patients</li>
                        <li>Stable Disease (SD): 4 patients</li>
                        <li>Progressive Disease (PD): 5 patients</li>
                    </ul>
                    <div class="chart-container my-4">
                        <svg id="prideResponseChart" width="350" height="280"></svg>
                        <div id="prideResponseLegend" class="legend"></div>
                    </div>
                    <p class="text-sm font-semibold mt-3 mb-1">Efficacy for Pts Completing 3 Cycles (N=16):</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>CR Rate: <strong>87.5%</strong> (14/16).</li>
                        <li>Subtypes:
                            <ul class="list-circle list-inside ml-4">
                                <li>MCD subtype (n=5): CR Rate 100%.</li>
                                <li>Other subtypes (n=7): CR Rate 80%.</li>
                            </ul>
                        </li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary (N=36)</h2>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Grade ≥3 Adverse Events (AEs): 61.1% of patients.</li>
                        <li><strong>Most Common AEs (any grade, specific rates not provided for all):</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>Thrombocytopenia</li>
                                <li>Neutropenia</li>
                                <li>Leukopenia</li>
                            </ul>
                        </li>
                        </ul>
                </div>
            </div> </div> <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>The PR-ICE regimen (Pomalidomide 2mg MTD + R-ICE) demonstrated high efficacy in this interim analysis for patients with R/R DLBCL after one prior line of therapy.</li>
                <li>CR rates were notably high (54.8% overall evaluable, 87.5% for those completing 3 cycles).</li>
                <li>The safety profile was acceptable, with manageable hematological toxicities being the most common Grade ≥3 AEs.</li>
                <li>These findings support further investigation of PR-ICE as a salvage therapy for R/R DLBCL.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>AE, Adverse Event; ChiCTR, Chinese Clinical Trial Registry; CR, Complete Remission; D, Day; DLBCL, Diffuse Large B-Cell Lymphoma; DLT, Dose-Limiting Toxicity; ECOG, Eastern Cooperative Oncology Group; EP, Endpoint; LOT, Lines of Therapy; MCD, A DLBCL subtype (MyD88 L265P and CD79B mutations); MTD, Maximum Tolerated Dose; ORR, Overall Response Rate; OS, Overall Survival; PCNSL, Primary Central Nervous System Lymphoma; PD, Progressive Disease; PFS, Progression-Free Survival; Pom, Pomalidomide; PO, Per Os (by mouth); PR, Partial Remission; PR-ICE, Pomalidomide + Rituximab, Ifosfamide, Carboplatin, Etoposide; Pts, Patients; Q21D, Every 21 Days; R-ICE, Rituximab, Ifosfamide, Carboplatin, Etoposide; R/R, Relapsed/Refractory; SD, Stable Disease.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Xu P, He Y, Cao Y, et al. Interim analysis of Pomalidomide plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (PR-ICE) in relapsed/refractory diffuse large B-cell lymphoma: A Phase I/II study (PRIDE Study). Abstract #PS1956 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PS1956 | Abstract Release: 05/14/25 | Presentation: 06/14/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div> <script defer src="abstract_features.js"></script>
    <script>
    function drawPrideResponseChart(containerId, legendContainerId) {
        const chartTitle = "Response to PR-ICE (N=31 Evaluable)";
        // ORR 70.9%, CRR 54.8%. PRR = 70.9 - 54.8 = 16.1%
        // SD 4/31 = 12.9%, PD 5/31 = 16.1%
        const chartData = [
            { response: "CR", rate: 54.8, color: "var(--sobi-teal)" },
            { response: "PR", rate: 16.1, color: "var(--sobi-light-teal-bg)" },
            { response: "SD", rate: 12.9, color: "var(--sobi-yellow)" },
            { response: "PD", rate: 16.1, color: "var(--sobi-red-light)" }
        ];
        const orrRate = chartData.find(d => d.response === "CR").rate + chartData.find(d => d.response === "PR").rate;

        const svg = d3.select(containerId);
        const legendContainer = d3.select(legendContainerId);
        svg.selectAll("*").remove();
        legendContainer.selectAll("*").remove();

        let containerWidth = 350;
        const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
        if (chartWrapper) {
            containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.90, 280);
        }
        
        const svgWidth = containerWidth;
        const svgHeight = +svg.attr("height");
        const margin = { top: 60, right: 20, bottom: 50, left: 50 };
        const chartWidth = svgWidth - margin.left - margin.right;
        const chartHeight = svgHeight - margin.top - margin.bottom;

        if (chartWidth <= 0 || chartHeight <=0) return;

        const g = svg.append("g").attr("transform", `translate(${margin.left},${margin.top})`);

        const xScale = d3.scaleBand()
            .domain(chartData.map(d => d.response))
            .range([0, chartWidth])
            .padding(0.2);

        const yScale = d3.scaleLinear().domain([0, 100]).range([chartHeight, 0]);

        g.append("g").attr("transform", `translate(0,${chartHeight})`).call(d3.axisBottom(xScale))
            .selectAll("text").attr("class", "axis-text").style("font-size", "10px");

        g.append("g").call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d + "%"))
            .selectAll("text").attr("class", "axis-text").style("font-size", "10px");
        
        g.append("text").attr("transform", "rotate(-90)").attr("y", 0 - margin.left + 10).attr("x", 0 - (chartHeight / 2))
            .attr("dy", "1em").style("text-anchor", "middle").attr("class", "axis-label").text("Response Rate (%)");

        g.append("g").attr("class", "grid")
            .call(d3.axisLeft(yScale).ticks(5).tickSize(-chartWidth).tickFormat(""))
            .selectAll("line").style("stroke", "var(--sobi-light-gray)").style("stroke-opacity", "0.7");

        g.selectAll(".bar").data(chartData).enter().append("rect")
            .attr("class", "bar").attr("x", d => xScale(d.response)).attr("y", d => yScale(d.rate))
            .attr("width", xScale.bandwidth()).attr("height", d => chartHeight - yScale(d.rate))
            .attr("fill", d => d.color).attr("rx", 3).attr("ry", 3);

        g.selectAll(".bar-label").data(chartData).enter().append("text")
            .attr("class", "chart-label").attr("x", d => xScale(d.response) + xScale.bandwidth() / 2)
            .attr("y", d => yScale(d.rate) - 5).attr("text-anchor", "middle")
            .style("font-size", "10px").style("fill", "var(--sobi-dark-text)")
            .text(d => `${d.rate.toFixed(1)}%`);
        
        svg.append("text").attr("x", svgWidth / 2).attr("y", margin.top / 2 - 5)
            .attr("text-anchor", "middle").style("font-size", "13px").style("font-weight", "600")
            .style("fill", "var(--sobi-dark-blue)").text(chartTitle);
        
        svg.append("text").attr("x", svgWidth / 2).attr("y", margin.top / 2 + 15)
            .attr("text-anchor", "middle").style("font-size", "11px").style("font-weight", "bold")
            .style("fill", "var(--sobi-teal-darker)").text(`Overall Response Rate (ORR): ${orrRate.toFixed(1)}%`);

        const legendItems = legendContainer.selectAll(".legend-item").data(chartData).enter().append("div").attr("class", "legend-item");
        legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
        legendItems.append("span").text(d => d.response);
    }
    
    function debounce(func, wait) {
        let timeout;
        return function executedFunction(...args) {
            const later = () => { clearTimeout(timeout); func(...args); };
            clearTimeout(timeout);
            timeout = setTimeout(later, wait);
        };
    };

    const debouncedDrawPrideChart = debounce(() => drawPrideResponseChart("#prideResponseChart", "#prideResponseLegend"), 250);
    
    window.addEventListener('resize', debouncedDrawPrideChart);
    document.addEventListener('DOMContentLoaded', debouncedDrawPrideChart);
    if (document.readyState === "complete" || document.readyState === "interactive") {
         setTimeout(debouncedDrawPrideChart, 0); 
    }
    </script>
</body>
</html>
